Morgan Stanley lowered the firm’s price target on Acelyrin (SLRN) to $5 from $6 and keeps an Equal Weight rating on the shares. The firm is updating its model to remove uveitis estimates following the ...

Phase 2b/3 trial of izokibep did not meet primary endpoint; secondary endpoints also did not achieve statistical significanceCompany continues ...